The potential use of urine cell free DNA as a marker for cancer

Expert Review of Molecular Diagnostics

Volumn 16, Issue 12, 2016, Pages 1283-1290

  Salvi, Samanta ^a   Martignano, Filippo ^a   Molinari, Chiara ^a   Gurioli, Giorgia ^a   Calistri, Daniele ^a   De Giorgi, Ugo ^a   Conteduca, Vincenza ^a   Casadio, Valentina ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

cancer; cell free DNA; liquid biopsy; markers; Urine

Indexed keywords

BIOPSY; CANCER DIAGNOSIS; CELL CULTURE MONITORING; GENETIC MARKER; HUMAN; HUMAN TISSUE; MEDLINE; PROGNOSIS; SYSTEMATIC REVIEW; URINE; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; MICROSATELLITE INSTABILITY; NEOPLASMS; UROLOGIC NEOPLASMS;

DNA; TUMOR MARKER;

BIOMARKERS, TUMOR; BIOPSY; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICROSATELLITE INSTABILITY; NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84996938017     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1080/14737159.2016.1254551     Document Type: Review

References (50)

1. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224–24.
2. Calistri D, Casadio V, Bravaccini S, et al. Urinary biomarkers of non-muscle-invasive bladder cancer:current status and future potential. Expert Rev Anticancer Ther. 2012;12(6):743–752.
3. Botezatu I, Serdyuk O, Potapova G, et al. Genetic analysis of DNA excreted in urine:a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem. 2000;46(8 Pt 1):1078–1084.• Pioneer study that deeply investigated the basis of PCR approaches for the study of transrenal DNA.
4. Tencer J, Frick I-M, Öquist BW, et al. Size-selectivity of the glomerular barrier to high molecular weight proteins:upper size limitations of shunt pathways. Kidney Int. 1998;53(3):709–715.
5. Su Y-H, Wang M, Brenner DE, et al. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn. 2004;6(2):101–107.• Interesting characterization of transrenal DNA fragmentation and its application for diagnosis of colorectal cancer.
6. Bryzgunova OE, Laktionov PP., Extracellular nucleic acids in urine:sources, structure, diagnostic potential. Acta Naturae. 2015;7(3):48–54.
7. Su Y-H, Wang M, Brenner DE, et al. Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci. 2008;1137:197–206.
8. Zancan M, Galdi F, Di Tonno F, et al. Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. Int J Biol Markers. 2009;24(3):147–155.
9. Chang HW, Tsui KH, Shen LC, et al. Urinary cell-free DNA as a potential tumor marker for bladder cancer. Int J Biol Markers. 2007;22(4):287–294.
10. Casadio V, Calistri D, Salvi S, et al. Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis:A pilot study. Biomed Res Int. 2013;08:1744–1750.
11. Xia Y, Huang -C-C, Dittmar R, et al. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget. 2016;7(24):35818–35831.•• First study that evaluated CNV in UcfDNA using NGS techniques.
12. Birkenkamp-Demtröder K, Nordentoft I, Christensen E, et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol. 2016;70:75–82.•• Study showing the capacity of UcfDNA to anticipate the clinical evidence of disease progression.
13. Togneri FS, Ward DG, Foster JM, et al. Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. Nat Publ Gr. 2016;1–8.•• Study showing that UcfDNA is more informative of bladder cancer mutation status than circulating cfDNA.
14. Utting M, Werner W, Dahse R, et al. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients:a minimally invasive method for the detection of bladder cancer. Clin Cancer Res. 2002;8:35–40.
15. Szarvas T, Kovalszky I, Bedi K, et al. Deletion analysis of tumor and urinary DNA to detect bladder cancer:urine supernatant versus urine sediment. Oncol Rep. 2007;18(2):405–409.
16. Bryzgunova OE, Morozkin ES, Yarmoschuk SV, et al. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann N Y Acad Sci. 2008;1137:222–225.• UcfDNA and plasma cfDNA for the study of GSTP1 promoter methylation in prostate cancer patients.
17. Song BP, Jain S, Lin SY, et al. Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J Mol Diagn. 2012;14(2):112–119.
18. Lin SY, Dhillon V, Jain S, et al. A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine. J Mol Diagn. 2011;13(5):474–484.
19. Reckamp KL, Melnikova VO, Karlovich C, et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol. 2016;11(10):S1556-0864(16)30587-1.•• Interesting comparison of UcfDNA and plasma cfDNA for the detection of EGFR mutation in NSCLC patients using NGS approach.
20. Chen S, Zhao J, Cui L, et al. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. Clin Transl Oncol. Forthcoming 2016. [Epub ahead of print].•• Comparison of UcfDNA and plasma cfDNA for the detection of EGFR mutation in NSCLC patients using droplet dPCR.
21. Su Y-H, Song J, Wang Z, et al. Removal of high-molecular-weight DNA by carboxylated magnetic beads enhances the detection of mutated K-ras DNA in urine. Ann N Y Acad Sci. 2008;1137:82–91.
22. Casadio V, Calistri D, Tebaldi M, et al. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis:preliminary data. Urol Oncol. 2013;31(8):1744–1750.• Innovative UcfDNA approach for the diagnosis of bladder cancer.
23. Salvi S, Gurioli G, Martignano F, et al. Urine cell-free DNA integrity analysis for early detection of prostate cancer patients. Dis Markers. 2015;574120.• Innovative UcfDNA approach for the diagnosis of prostate cancer.
24. Tsui NBY, Jiang P, Chow KCK, et al. High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. PLoS One. 2012;7(10):e48319.
25. Melkonyan HS, Feaver WJ, Meyer E, et al. Transrenal nucleic acids:from proof of principle to clinical tests. Ann N Y Acad Sci. 2008;1137:73–81.
26. Ghanjati F, Beermann A, Hermanns T, et al. Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA. Cancer Biomark. 2014;14(5):295–302.
27. García Moreira V, Prieto García B, De La Cera Martínez T, et al. Elevated transrenal DNA (cell-free urine DNA) in patients with urinary tract infection compared to healthy controls. Clin Biochem. 2009;42(7–8):729–731.
28. Yao W, Mei C, Nan X, et al. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva:a qualitative study. Gene. 2016;590(1):142–148.
29. Vaara ST, Lakkisto P, Immonen K, et al. Urinary biomarkers indicative of apoptosis and acute kidney injury in the critically ill. PLoS One. 2016;11(2):1–13.
30. Zancan M, Franceschini R, Mimmo C, et al. Free DNA in urine:a new marker for bladder cancer? Preliminary data. Int J Biol Markers. 2005;20(2):134–136.
31. Hyman DM, Diamond EL, Vibat CRT, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015;5(1):64–71.• Study that underlies the potential of UcfDNA for the detection of BRAFV600E mutation in nonurological diseases.
32. Skvortsova TE, Rykova EY, Tamkovich SN, et al. Cell-free and cell-bound circulating DNA in breast tumours:DNA quantification and analysis of tumour-related gene methylation. Br J Cancer. 2006;94(10):1492–1495.
33. Hao TB, Shi W, Shen XJ, et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014;111(8):1482–1489.
34. Zonta E, Nizard P, Taly V. Assessment of DNA integrity, applications for cancer research. Adv Clin Chem. 2015;70:197–246.
35. Frenel JS, Carreira S, Goodall J, et al. Serial next-generation sequencing of circulating cell-free dna evaluating tumor clone response to molecularly targeted drug administration. Clin Cancer Res. 2015;21(20):4586–4596.
36. Salvi S, Casadio V, Conteduca V, et al. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget. 2016;7(25):37839–37845.
37. Diaz LA, Bardelli A. Liquid biopsies:genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–586.
38. Fujii T, Vibat CRT, Karp DD, et al. Circulating tumor DNA assay performance for detection and monitoring of KRAS mutations in urine from patients with advanced cancers. AACR Meet. #3146; 16–20 Apr, New Orleans:Ernest N. Morial Convention Center. 2016.•• Innovative characterization with NGS techniques of UcfDNA in nonurological cancers.
39. Janku F, Vibat CRT, Falchook GS, et al. Low frequency KRAS G12 /13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers cfDNA KRAS and BRAF assays. ASCO Annu. Meet. #11048; 29th May to 2nd Jun, Chicago:McCormick Place. 2015.•• Innovative characterization with NGS techniques of UcfDNA in nonurological cancers.
40. Husain H, Kosco K, Vibat CRT, et al. Kinetic monitoring of EGFR exon 19 del, L858R, and T790M in urinary circulating tumor DNA predicts radiographic progression and response in patients with metastatic lung adenocarcinoma EGFR ctDNA assay. ASCO Annu. Meet. #8081; 29th May to 2nd Jun, Chicago:McCormick Place. 2015.
41. Wakelee HA, Gadgeel SM, Wade Goldman J, et al. Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. J Clin Oncol. 2016;34:9001.•• Innovative characterization with NGS techniques of UcfDNA in NSCLC.
42. Eisenberger CF, Schoenberg M, Enger C, et al. Diagnosis of renal cancer by molecular urinalysis. JNCI J Natl Cancer Inst. 1999;91(23):2028–2032.
43. Sarkar S, Horn G, Moulton K, et al. Cancer development, progression, and therapy:an epigenetic overview. Int J Mol Sci. 2013;14(10):21087–21113.
44. Ellinger J, Müller SC, Dietrich D. Epigenetic biomarkers in the blood of patients with urological malignancies. Expert Rev Mol Diagn. 2015;15(4):505–516.
45. Henrique R, Jerónimo C. Molecular detection of prostate cancer:a role for GSTP1 hypermethylation. Eur Urol. 2004;46(5):660–669.
46. Sengar M, Chorghe S, Jadhav K, et al. Cell-free Epstein–Barr virus-DNA in patients with nasopharyngeal carcinoma:plasma versus urine. Head Neck. 2016;38:E1666–E1673.
47. Guerrero-Preston R, Valle BL, Jedlicka A, et al. Molecular triage of premalignant lesions in liquid-based cervical cytology and circulating cell free DNA from urine, using methylated viral and host genes. Cancer Prev Res. Forthcoming 2016. [Epub ahead of print].
48. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–123.
49. Janku F, Rose C, Vibat T, et al. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget. 2014;5(11):3607–3610.
50. Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERGPlus PCA3 for individualized prostate cancer risk assessment. Eur Urol. 2016;70(1):45–53.